ARK1B10, a 316A.A protein, catalyzes efficient reduction ofaliphatic and aromatic aldehydes. It the first cytosolic NADP (H)-dependent retinal reductase described in humans and is characterized by the presence of a novel NADP binding motif. Due to its ability to convert glucose to sorbitol, AKR1B10 may have a role in development of secondary diabetic complications.It is abundantly expressed in adrenal gland, small intestine and colon, with lower levels in liver, thymus, prostate, testis, and skeletal muscle and its levels are up regulated in certain cancers such as hepatocellular carcinoma.
Immunogen
A portion of amino acids 100-200 of human AKR1B10 protein.
Key Feature
Clonality
Polyclonal
Host Species
Rabbit
Tested Applications
IHCWB
AKR1B10 antibody can be used in ELISA, Western Blot, and immunohistochemistry starting at 5 μg/mL.: